Analysts are expecting a payout of $6 a share from Fresenius Kabi Pharmaceuticals Holdings inc. (NASDAQ: APCVZ) to its owners following the release of its annual report later this month.This would be an additional cash payment from a merger that took place on September 10, 2008 when Fresenius Kabi Pharmaceuticals Holdings completed the acquisition of APP Pharmaceuticals, Inc. The holders of APCVZ are entitled to an additional payment which analysts project will be $6 a share.
The company is expected to announce this payout shortly after releasing its fourth quarter results.
The closing price for Fresenius Kabi Pharmaceuticals Holdings inc. (APCVZ) last Friday was around $0.05 per share.
The analyst report was issued by Crixion, Inc., an independent analysis firm that specializes in finding securities with hidden value. “We believe it's one of the least understood and most undervalued security out there today.” Says one of the analysts for Crixion.
“The number of new products and services launched in 2010 make it very likely that we will see a payment of this size. We have made a comprehensive analysis of this security and found it to be extremely undervalued in our opinion. We are among few analysts that follow this security and its value is not well understood among investors and most are completely unaware of the hidden value of this merger payout,” concluded the analyst from Crixion.
Crixion is an independent Security analysis firm for investors seeking hidden value. Crixion does not receive income in any other way than by selling its reports and does not invest in any securities.
No comments:
Post a Comment